IBM Secures $112M Contract with Department of War
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy BLCO?
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.TARIFF REFUNDS:Bausch + Lomb, L'Oreal, and Dyson are suing for refunds of tariffs paid under President Donald Trump's emergency trade measures, days after the U.S. Supreme Court ruled the duties unlawful, Arriana McLymore of Reuters. More than 1,400 importers including Costcoand Goodyearhave already sued, court documents show, and trade lawyers expect a wave of additional lawsuits as companies try to recover billions of dollars in duties. FedExalso filed a complaint this week.CITIZENSHIP INFO:President Trump's administration is weighing a possible executive order or other action that would require banks to collect citizenship information from customers in "a new front in the administration's crackdown on immigrants living in the U.S. illegally," according to's Dylan Tokar and Natalie Andrews, citing people familiar with the matter. Ultimately, banks may be tasked with asking for an unprecedented new category of documents, such as a passport, from both new and pre-existing customers who want to maintain a U.S. bank account, the report stated. Publicly traded large cap banks include Bank of America, Citi, Goldman Sachs, JPMorgan, Morgan Stanley, U.S. Bancorpand Wells Fargo.DOW CONTRACT:IBMhas secured a contract with a ceiling value of $112M for up to five years from the Department of War's, or DoW, Defense Commissary Agency, or DeCA, to modernize pricing displays across commissaries worldwide, aimed to enhance operational efficiency and improve the shopping experience for military personnel and their families. This investment represents a step in advancing digital retail infrastructure for the DoW. Under the agreement, IBM will upgrade the existing Electronic Shelf Label system at 177 U.S. commissaries and install new systems at 58 overseas locations in 12 countries. Additional expected benefits of the new ESL system include: Accurate pricing and availability: Enables real-time price updates and enhanced product availability for military personnel and their families; Operational efficiency: Streamlines processes to reduce manual labor, aligning with the DoW's digital transformation goals. As part of the contract, IBM will provide hardware maintenance, software licenses, security, vulnerability mitigation, training, and ongoing support for existing ESL infrastructure - including proprietary Pricer ESL software and hardware, third-party components such as Windows operating systems, and the web-based ordering platform integrated within DeCA's environment. Overseas installations are scheduled to begin in early 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLCO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLCO
Wall Street analysts forecast BLCO stock price to rise
10 Analyst Rating
4 Buy
5 Hold
1 Sell
Moderate Buy
Current: 15.840
Low
13.00
Averages
18.11
High
21.00
Current: 15.840
Low
13.00
Averages
18.11
High
21.00
About BLCO
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bausch + Lomb Achieves Key Milestone in Glaucoma Treatment with ELIOS System
- Clinical Trial Success: Bausch + Lomb's ELIOS System successfully met its dual primary efficacy endpoints in glaucoma trials, with 76% of patients achieving a reduction of 20% or more in unmedicated intraocular pressure, indicating the technology's effectiveness and potential market prospects.
- Significant Pressure Reduction: The trial demonstrated an average decrease of 7.4 mmHg in patients' intraocular pressure, which not only highlights the therapeutic potential of the ELIOS System but also suggests a possible increase in the company's market share in glaucoma treatment.
- Long-term Medication-Free: At 23 months follow-up, 82% of patients remained medication-free, enhancing patient quality of life and solidifying Bausch + Lomb's leadership position in glaucoma management.
- Technological Innovation and Market Recognition: The ELIOS System utilizes excimer laser technology and has received CE marking in Europe, signifying international market acceptance and is expected to provide robust support for the company's future revenue growth and market expansion.
See More
Bausch + Lomb Reports Positive ELIOS System Clinical Trial Results
- Clinical Trial Success: Bausch + Lomb announced that its ELIOS System achieved positive results in a pivotal U.S. clinical trial, with 76% of patients experiencing over a 20% reduction in unmedicated intraocular pressure (IOP), demonstrating both efficacy and clinical significance of the technology.
- Safety and Efficacy: Among 318 participants, the ELIOS procedure showed no intraoperative complications, and the postoperative adverse event rate was similar to that of cataract surgery alone, indicating a strong safety profile that could position it as a new option for glaucoma treatment.
- Market Potential: The ELIOS system is CE marked in Europe and has been validated through 12 clinical studies, showing a 20-40% reduction in IOP and 81% of patients medication-free within a year, suggesting a promising outlook for its adoption in the U.S. market.
- Future Outlook: Bausch + Lomb plans to submit detailed results to future medical meetings and peer-reviewed journals, further advancing the clinical application of ELIOS technology and reinforcing its leadership position in the ophthalmic field.
See More
Caspian Capital Increases Stake in Bausch + Lomb Corporation
- Share Acquisition: On February 17, 2026, Caspian Capital disclosed the purchase of 1,349,043 shares of Bausch + Lomb Corporation, with an estimated trade value of $21.39 million, indicating strong confidence and investment intent in the company.
- Increased Ownership: Following this acquisition, Caspian Capital's stake in Bausch + Lomb now represents 22.58% of its 13F reportable AUM, making it one of the firm's top holdings and reflecting a strategic focus on the eye health market.
- Financial Performance: Bausch + Lomb generated $5.1 billion in revenue for 2025, a 6% increase year-over-year, with fourth-quarter sales reaching $1.405 billion, up 10%, demonstrating robust demand in the eye care product sector.
- Market Outlook: Although the stock has underperformed over the past year, the company is actively addressing rising global demand for eye health through new product launches like the dry eye therapy MIEBO, positioning itself for potential future investment returns.
See More
Caspian Capital Increases Stake in Bausch + Lomb Corporation
- Stake Increase: In Q4 2026, Caspian Capital increased its stake in Bausch + Lomb by 1,349,043 shares, with an estimated trade value of $21.39 million, indicating strong confidence and investment intent in the company.
- Position Value Rise: Following the purchase, Caspian Capital's total holding in Bausch + Lomb reached 1,999,043 shares valued at $34.14 million, reflecting positive impacts from both the trade and stock price movements.
- Performance Growth: Bausch + Lomb generated $5.1 billion in revenue for 2025, a 6% increase year-over-year, with Q4 sales climbing 10% to $1.405 billion, showcasing its robust performance in the eye health market.
- Market Outlook: Although the stock has underperformed over the past year, the rising demand for eye care driven by aging populations and increased screen usage suggests that Bausch + Lomb's product portfolio could further propel future growth.
See More
Bausch + Lomb Launches First R&D Webinar Series
- Webinar Series Launch: Bausch + Lomb announced the first event in its R&D 'Teach-in' webinar series scheduled for March 23, 2026, aimed at providing deeper insights into its differentiated product pipeline, particularly innovative treatments for glaucoma.
- Glaucoma Drug Development: The webinar will highlight BL1107, an under-development glaucoma medication expected to be the first to lower intraocular pressure while treating vision loss, presenting significant market potential.
- Minimally Invasive Surgery: ELIOS™ is an implant-free minimally invasive glaucoma surgery approach that uses excimer laser precision to create outflow channels, already commercialized in Europe and supported by extensive clinical data, with a U.S. launch anticipated in the second half of 2026.
- Executive Participation: Bausch + Lomb's executive team, including CEO Brent Saunders and CFO Sam Eldessouky, will participate in the webinar, showcasing the company's commitment to innovation and strategic positioning in the eye health market.
See More
Bausch + Lomb Reports Record Q4 2025 Earnings Performance
- Record Performance: Bausch + Lomb achieved $1.405 billion in revenue and $330 million in adjusted EBITDA for Q4 2025, reflecting a 9.7% and 23.5% increase from the previous quarter, respectively, demonstrating the company's strong commitment to financial excellence.
- Dry Eye Product Growth: Miebo generated $112 million in Q4 revenue with a remarkable 111% year-over-year growth, successfully crossing the 2 million prescription mark, indicating a shift towards profitability and solidifying the company's leadership in the dry eye market.
- Optimistic Outlook: Management set 2026 full-year revenue guidance between $5.375 billion and $5.475 billion, reflecting a 5% to 7% growth, while adjusted EBITDA guidance is projected at $1 billion to $1.050 billion, showcasing confidence in future profitability.
- Ongoing Strategic Investment: The company plans to allocate 7.5% to 8% of revenue for R&D investments and expects capital expenditures of approximately $285 million, aiming to drive long-term growth through continuous innovation and product development.
See More
Bausch + Lomb Achieves Key Milestone in Glaucoma Treatment with ELIOS System
- Clinical Trial Success: Bausch + Lomb's ELIOS System successfully met its dual primary efficacy endpoints in glaucoma trials, with 76% of patients achieving a reduction of 20% or more in unmedicated intraocular pressure, indicating the technology's effectiveness and potential market prospects.
- Significant Pressure Reduction: The trial demonstrated an average decrease of 7.4 mmHg in patients' intraocular pressure, which not only highlights the therapeutic potential of the ELIOS System but also suggests a possible increase in the company's market share in glaucoma treatment.
- Long-term Medication-Free: At 23 months follow-up, 82% of patients remained medication-free, enhancing patient quality of life and solidifying Bausch + Lomb's leadership position in glaucoma management.
- Technological Innovation and Market Recognition: The ELIOS System utilizes excimer laser technology and has received CE marking in Europe, signifying international market acceptance and is expected to provide robust support for the company's future revenue growth and market expansion.
See More
Bausch + Lomb Reports Positive ELIOS System Clinical Trial Results
- Clinical Trial Success: Bausch + Lomb announced that its ELIOS System achieved positive results in a pivotal U.S. clinical trial, with 76% of patients experiencing over a 20% reduction in unmedicated intraocular pressure (IOP), demonstrating both efficacy and clinical significance of the technology.
- Safety and Efficacy: Among 318 participants, the ELIOS procedure showed no intraoperative complications, and the postoperative adverse event rate was similar to that of cataract surgery alone, indicating a strong safety profile that could position it as a new option for glaucoma treatment.
- Market Potential: The ELIOS system is CE marked in Europe and has been validated through 12 clinical studies, showing a 20-40% reduction in IOP and 81% of patients medication-free within a year, suggesting a promising outlook for its adoption in the U.S. market.
- Future Outlook: Bausch + Lomb plans to submit detailed results to future medical meetings and peer-reviewed journals, further advancing the clinical application of ELIOS technology and reinforcing its leadership position in the ophthalmic field.
See More
Caspian Capital Increases Stake in Bausch + Lomb Corporation
- Share Acquisition: On February 17, 2026, Caspian Capital disclosed the purchase of 1,349,043 shares of Bausch + Lomb Corporation, with an estimated trade value of $21.39 million, indicating strong confidence and investment intent in the company.
- Increased Ownership: Following this acquisition, Caspian Capital's stake in Bausch + Lomb now represents 22.58% of its 13F reportable AUM, making it one of the firm's top holdings and reflecting a strategic focus on the eye health market.
- Financial Performance: Bausch + Lomb generated $5.1 billion in revenue for 2025, a 6% increase year-over-year, with fourth-quarter sales reaching $1.405 billion, up 10%, demonstrating robust demand in the eye care product sector.
- Market Outlook: Although the stock has underperformed over the past year, the company is actively addressing rising global demand for eye health through new product launches like the dry eye therapy MIEBO, positioning itself for potential future investment returns.
See More
Caspian Capital Increases Stake in Bausch + Lomb Corporation
- Stake Increase: In Q4 2026, Caspian Capital increased its stake in Bausch + Lomb by 1,349,043 shares, with an estimated trade value of $21.39 million, indicating strong confidence and investment intent in the company.
- Position Value Rise: Following the purchase, Caspian Capital's total holding in Bausch + Lomb reached 1,999,043 shares valued at $34.14 million, reflecting positive impacts from both the trade and stock price movements.
- Performance Growth: Bausch + Lomb generated $5.1 billion in revenue for 2025, a 6% increase year-over-year, with Q4 sales climbing 10% to $1.405 billion, showcasing its robust performance in the eye health market.
- Market Outlook: Although the stock has underperformed over the past year, the rising demand for eye care driven by aging populations and increased screen usage suggests that Bausch + Lomb's product portfolio could further propel future growth.
See More
Bausch + Lomb Launches First R&D Webinar Series
- Webinar Series Launch: Bausch + Lomb announced the first event in its R&D 'Teach-in' webinar series scheduled for March 23, 2026, aimed at providing deeper insights into its differentiated product pipeline, particularly innovative treatments for glaucoma.
- Glaucoma Drug Development: The webinar will highlight BL1107, an under-development glaucoma medication expected to be the first to lower intraocular pressure while treating vision loss, presenting significant market potential.
- Minimally Invasive Surgery: ELIOS™ is an implant-free minimally invasive glaucoma surgery approach that uses excimer laser precision to create outflow channels, already commercialized in Europe and supported by extensive clinical data, with a U.S. launch anticipated in the second half of 2026.
- Executive Participation: Bausch + Lomb's executive team, including CEO Brent Saunders and CFO Sam Eldessouky, will participate in the webinar, showcasing the company's commitment to innovation and strategic positioning in the eye health market.
See More
Bausch + Lomb Reports Record Q4 2025 Earnings Performance
- Record Performance: Bausch + Lomb achieved $1.405 billion in revenue and $330 million in adjusted EBITDA for Q4 2025, reflecting a 9.7% and 23.5% increase from the previous quarter, respectively, demonstrating the company's strong commitment to financial excellence.
- Dry Eye Product Growth: Miebo generated $112 million in Q4 revenue with a remarkable 111% year-over-year growth, successfully crossing the 2 million prescription mark, indicating a shift towards profitability and solidifying the company's leadership in the dry eye market.
- Optimistic Outlook: Management set 2026 full-year revenue guidance between $5.375 billion and $5.475 billion, reflecting a 5% to 7% growth, while adjusted EBITDA guidance is projected at $1 billion to $1.050 billion, showcasing confidence in future profitability.
- Ongoing Strategic Investment: The company plans to allocate 7.5% to 8% of revenue for R&D investments and expects capital expenditures of approximately $285 million, aiming to drive long-term growth through continuous innovation and product development.
See More
